Cerebral Venous Thrombosis (CVT)

Last updated: April 20, 2019

[Epidemiology 1](#_Toc6624574)

[Etiology 1](#_Toc6624575)

[Pathophysiology 1](#_Toc6624576)

[Clinical Features 2](#_Toc6624577)

[Superior sagittal sinus thrombosis 2](#_Toc6624578)

[Lateral sinus thrombosis 2](#_Toc6624579)

[Cavernous sinus thrombosis 3](#_Toc6624580)

[Diagnosis 3](#_Toc6624581)

[Imaging 3](#_Toc6624582)

[MRI 3](#_Toc6624583)

[MRV 3](#_Toc6624584)

[CT 4](#_Toc6624585)

[CTV 5](#_Toc6624586)

[Arteriography 5](#_Toc6624587)

[Other Studies 5](#_Toc6624588)

[EEG 5](#_Toc6624589)

[Lumbar puncture 5](#_Toc6624590)

[Funduscopy 5](#_Toc6624591)

[Blood 5](#_Toc6624592)

[Urine 6](#_Toc6624593)

[Differential 6](#_Toc6624594)

[Treatment 6](#_Toc6624595)

[Medical 6](#_Toc6624596)

[Surgical 7](#_Toc6624597)

[Prognosis 7](#_Toc6624598)

[Follow up 7](#_Toc6624599)

CVT - thrombosis of venous sinuses, superficial or deep cerebral veins.

Epidemiology


* 0.5-1% of all strokes.
* **female**-to-male ratio 1.29-3 : 1
* any age (newborn to elderly patients); 80% patients are < 50 yrs; age distribution:

**men** - uniform age distribution;

**women** - 61% aged 20-35 yrs (may be related to pregnancy or oral contraceptives)

* mean age at presentation is nearly 1 decade younger in women compared to men (34 years vs. 42 years).

Age and sex distribution of cerebral venous and sinus thrombosis (CVT) in adults:



Dr Jose Ferro from the International Study on Cerebral Venous and Dural Sinuses Thrombosis

Etiology

1. **Infection** extension from **paranasal sinuses, middle ear** (via emissary veins), **face**, **oropharynx** → suppurative intracranial thrombophlebitis.

N.B. orbital veins (drain from middle third of face, including paranasal sinuses) have no valves - allow infection passage both *anterograde* and *retrograde*!

* may be associated with epidural abscess, subdural empyema, meningitis, cranial osteomyelitis.
* frontal sinuses are most common source.
* most commonly - lateral and cavernous sinuses.
* *Staphylococcus aureus* is most common.

1. **Trauma**:
   1. mild closed injury ÷ depressed skull fracture (occludes dural sinus)
   2. iatrogenic - dural taps, infusions into internal jugular vein.
2. **Tumors** – local compression, hypercoagulable state, antineoplastic drugs (e.g. tamoxifen, L-asparaginase).
3. **Hypercoagulable states** (present in 21% cases)
   * 1. antiphospholipid and anticardiolipin antibodies, protein S and C deficiencies, antithrombin III deficiency, lupus anticoagulant, Leiden factor V mutation, hyperhomocysteinemia
     2. paroxysmal nocturnal hemoglobinuria, thrombotic thrombocytopenic purpura, sickle cell disease, polycythemia.
     3. **pregnancy and puerperium**!!!
     4. disseminated malignancies (paraneoplastic hypercoagulation)
     5. sarcoidosis, inflammatory bowel diseases (Crohn), collagenoses (incl. corticosteroids used in treatment).
     6. vasculitis (such as Behcet syndrome).
     7. nephrotic syndrome, hepatic cirrhosis.
     8. dehydration, cachexia (“marantic” thrombosis in infancy) - superior sagittal sinus is most common.
4. **Medications**: **oral contraceptives** (incl. 3rd-generation), corticosteroids; ε-aminocaproic acid, L-asparaginase, heparin (thrombotic thrombocytopenia with venous sinus thrombosis).

Pathophysiology

**Cerebral venous thrombosis** is uncommon cause of cerebral **infarction** (relative to arterial disease).

venous strokes : arterial strokes ≈ 1 : 62.5

* venous occlusion → tissue congestion → early severe vasogenic brain edema → venous infarction → cytotoxic edema:

*venous sinus thrombosis* - infarction in cortex and adjacent white matter;

*deep cerebral vein thrombosis* - infarction in basal ganglia, thalamus.


* venous sinus system itself lacks valves, permitting retrograde propagation of clots - thrombosis from **dural sinuses** may progress (esp. in septic thrombosis) to **cortical veins**.
  + obstruction of cortical veins (e.g. vein of Labbé) can produce significant damage.
  + although unusual, cortical vein thrombosis may be seen in absence of dural sinus involvement.
* back-transmission of high pressure into capillary bed usually results in significant ***hemorrhagic component***.
* **SAH** also may be presenting feature (due to venous hypertension).
  + CVT should be considered in workup of SAH, esp. when basilar cisterns are not involved!
* *if sinus occlusion occurs gradually* (as by neo­plastic invasion), collateral drainage routes (incl. scalp veins) are recruited, thus avoiding cere­bral edema and ICP↑.
* venous thrombi are ***rich in RBCs and fibrin*** but poor in platelets ("red thrombus") → replaced by fibrous tissue with time.

Venous infarcts *do not conform to arterial territories*, are often *hemorrhagic* and *multifocal*.

Frequency:

1. superior sagittal sinus (70%, but less common site of infective thrombosis) – bilateral parasagittal more or less symmetric infarcts – most severe damage!
2. transverse (lateral) sinuses
3. cavernous sinus
4. inferior sagittal sinus, straight sinus, petrosal sinuses, vein of Galen - usually involved by secondary extension.

MRV showing the most frequent (%) location of cerebral venous and sinus thrombosis, as reported in the International Study on Cerebral Venous and Dural Sinuses Thrombosis (n=624):



Clinical Features

* course is more severe in septic thrombosis.
* course is mildest in isolated cortical vein thrombosis.

1. **Signs of ICP**↑ (impaired venous outflow)
2. **headache** - most common symptom! (90%); diffuse, increases over several days; thunderclap headache indicates associated SAH!!!
3. **nausea & vomiting**
4. **normal ÷ decreased level of consciousness** (may progress to coma)
5. **papilledema**
6. distention of the scalp veins may be noted.
7. **Focal neurological deficit** (focal brain injury from venous ischemia/infarction or hemorrhage; 75% patients) - depending on area involved as ***thrombus extends to cortical veins*** (CN syndromes, hemiparesis, facial weakness, aphasia, ataxia, hemianopia, deafness, etc).

N.B. focal neurologic signs may be entirely absent with ICP↑ pressure as only presenting sign!

* **seizures** are more common (40%) than in arterial strokes!; can be recurrent.
* *bilateral* brain involvement is not infrequent.

Clinical patterns:

* 1. isolated intracranial hypertension (mimicking pseudotumor cerebri)
  2. focal neurological signs (simulating arterial strokes or seizures)
  3. cavernous sinus syndrome.

Symptoms related to area of thrombosis:

Superior sagittal sinus thrombosis

* **weakness in lower extremity** (unilateral or paraparesis) → **hemiparesis** (secondary to clot extension into cerebral veins).
* *in infants* - ***forehead edema***, ***vein engorgement*** in area of anterior or posterior fontanels (caput medusae).
* bilateral involvement can produce ***stupor*** early in course.
* seizures in > ½ patients.
* course is frequently fulminant and prognosis guarded, although complete recovery may occur.

Lateral sinus thrombosis

* usually secondary to pediatric otitis media and mastoiditis (most patients are febrile with earache).
* swelling over mastoid region with distention of superficial veins.
* **Griesinger sign** - mastoid emissary vein thrombosis due to thrombus extension from sigmoid sinus.
* pseudotumor cerebri–like picture (ICP↑) – more common with right sinus occlusion (in most individuals, right sinus drains greater portion of brain).
* may produce otitic hydrocephalus.
* most common focal sign – ***CN6 palsy***.
* **extension into jugular bulb** → tenderness over jugular vein in neck, jugular foramen syndrome (Vernet): CN 9-11

Cavernous sinus thrombosis

* *septic thrombosis (*S. aureus 66%) *is associated with bacterial sinusitis (*sphenoidal or ethmoidal) or *orbital cellulitis*; nonseptic thrombosis is rare!
* involves only one sinus at onset but rapidly spreads (via circular sinus) to opposite side.
* onset is usually sudden and dramatic - patient appears acutely ill with fever; > ½ patients have change in mental status.
* ***cranial nerve palsies*** (compressive phenomenon) → variable ophthal­moplegia (esp. early CN6 palsy), ptosis, decreased sensation in CN51-2 divisions.
* ***obstruction of ophthalmic veins*** → periorbital edema (!), proptosis, chemosis, papilledema with hemorrhages around disc; orbits are painful to pressure.
* *septic thrombosis has high mortality.*

Diagnosis

Imaging

MRI

* + - acutely sinus walls appear convex
    - intensity follows blood intensity in ICH

1. absence of flow void in venous channels.


N.B. *acute thrombus* can appear hypointense on spinT2 (mimics flow void!!!); *slow flowing blood* may appear bright (mimics thrombus); H: MRV

1. edema and infarct (unilateral or bilateral or single or multifocal) that does not follow distribution of expected arterial occlusion.
2. ***hemorrhagic infarction*** is commonly found (because of increased pressure in draining veins).
3. chronic organizing thrombus develops ***significant neovascularity*** - ***enhances strongly*** demonstrating "frayed" or "shaggy" appearance.

**Transverse sinus thrombosis**:

A. Unenhanced coronal T1-MRI - high signal in right cerebellar hemisphere due to hemorrhage; absence of flow void and high signal in right transverse sinus (*arrow*).

B. Enhanced coronal T1-MRI - hemorrhagic infarct better defined and thrombus in right transverse sinus (*arrow*) is demarcated by enhancing walls of sinus.



MRV


- excellent method of visualizing dural venous sinuses and larger cerebral veins.


* single-slice phase-contrast angiography (SSPCA) takes < 30 seconds and provides rapid and reliable information (depicts only flow and not thrombus) - procedure of choice in diagnosing CVT (specificity and sensitivity 100%).

N.B. transverse sinus flow gaps (in nondominant or codominant transverse sinus) should not be mistaken for thrombosis.


"empty delta" sign; note prominent sulcal enhancement caused by collateral venous drainage (mimics meningitis):









Late acute DST:







CT

May be normal!

- may show evidence of infarction (edema) that does not correspond to arterial distribution.

* useful in ***ruling out other conditions*** – neoplasm, subdural empyema, sinusitis.
* demonstration of infarct may be delayed up to 48-72 hours.
* hemorrhagic infarction:


parasagittally located - superior sagittal sinus;

centrally located - straight sinus;

temporal located - transverse and sigmoid sinuses.


* **empty δ sign** on contrast CT (most specific CT finding) - nonenhanced thrombus in superior sagittal sinus surrounded by enhancement of engorged collateral veins around sinus and in sinus walls.
* **dense triangle sign** - fresh coagulated blood in superior sagittal sinus.
* **cord sign** - thrombosed cortical vein.

Axial CT - cavernous sinus (CS) is distended, with abscess (*arrowheads*); stenosis of intracavernous ICA is response to abscess:



* normal dura and circulating blood are mildly hyperdense compared to brain on CT scans, so subtle increased attenuation of venous thrombi can be difficult to detect.
* venous sinuses lie directly adjacent to skull, so clots can also be obscured by attenuation artifacts.

"empty delta" sign - enhancing dura surrounding nonenhancing thrombus:





Hyperdensity of right transverse sinus:




CTV

- equivalent to (or better than) MRV in identification of dural sinus thrombosis.

Arteriography

- with delayed filming technique (to visualize venous system) - was procedure of choice prior to advent of MRV.

* indicated only if MR studies are not diagnostic.
* intraluminal filling defects, flow absence within dural sinus.
* delayed emptying of cortical veins appear as if they are "***hanging in space***”.
* narrowing of intracavernous ICA in cavernous sinus thrombosis.
* **direct venography** - passing catheter from jugular vein into transverse sinus.
* **orbital venography** is most definitive method for cavernous sinus thrombosis.



Other Studies

EEG

- normal ÷ mild generalized slowing or focal abnormalities.

Lumbar puncture

1. evaluation for **meningitis**
2. ***compression of jugular vein unilaterally with pressure measurement*** (now rarely used) → pressure↑ if contralateral transverse sinus is thrombosed (collateral circulation or incomplete compression of jugular vein may yield *false-negative result*); elevation of intracranial venous pressure *may precipitate herniation*!

* CSF may be bloody or xanthochromic with parameningeal inflammatory profile and pressure↑.

Funduscopy

- papilledema.

Blood

**CBC** - leukocytosis (sepsis), polycythemia, platelet count↓ (thrombotic thrombocytopenic purpura).

D-dimer > 500 ng/mL may be beneficial in screening headache patients in ED.

* + D-dimers are *positively correlated* with **thrombosis extent** and *negatively correlated* with **symptom duration**.
  + sensitivity ≈ 97.1%, negative predictive value ≈ 99.6%, specificity ≈ 91.2%, positive predictive value ≈ 55.7%.

Hypercoagulable workup:

1. antithrombin
2. protein C, protein S
3. factor V Leiden
4. prothrombin gene G20210A mutation
5. lupus anticoag
6. anticardiolipin antibodies
7. anti beta2 glycoprotein-1 antibodies
8. sickle cell preparation / Hb electrophoresis (individuals of African decent), ESR & antinuclear antibody, liver function tests (cirrhosis).

* tests for hypercoagulable states should not be made while patient is on anticoagulants.

Urine

- nephrotic syndrome.


Differential

Anatomic variants of normal venous anatomy may mimic sinus thrombosis:

* + 1. sinus atresia/hypoplasia
    2. asymmetrical sinus drainage (20% of population has partial or complete absence of 1 lateral sinus)
    3. prominent arachnoid granulations
    4. intrasinus septa.

Treatment

AHA/ASA Scientific Statement on Cerebral Venous Thrombosis (2011):



†Intracranial hemorrhage that occurred as the consequence of CVST is not a contraindication for anticoagulation. ‡Endovascular therapy may be considered in patients with absolute contraindications for anticoagulation therapy or failure of initial therapeutic doses of anticoagulant therapy.

Medical

1. **Hydration**!
2. **Anticoagulation** in therapeutic doses ASAP (heparin → warfarin INR goal of 2-3) even if hemorrhagic infarction is present!!!!!!
   * **LMWH** may be preferable to unfractionated heparin.
   * duration: for ***unprovoked*** thromboses - 6-12 months → reimage and decide for continued anticoagulation; if patient is ***prothrombotic***, duration is indefinite.
   * may be followed with aspirin (role unclear).

AHA/ASA Scientific Statement on Cerebral Venous Thrombosis (2011):

* initial anticoagulation with adjusted-dose UFH or weight-based LMWH in full anticoagulant doses is reasonable, followed by vitamin K antagonists, regardless of the presence of ICH (Class IIa; Level of Evidence B).
* in patients with *provoked* CVT (associated with a transient risk factor), vitamin K antagonists may be continued for 3-6 months, with a target INR of 2.0-3.0 (Class IIb; Level of Evidence C).
* in patients with *unprovoked* CVT, vitamin K antagonists may be continued for 6-12 months, with a target INR of 2.0-3.0 (Class IIb; Level of Evidence C).
* for patients with *recurrent CVT, VTE after CVT, or first CVT with severe thrombophilia* indefinite anticoagulation may be considered, with a target INR of 2.0-3.0 (Class IIb; Level of Evidence C).

CVT during pregnancy

AHA/ASA Scientific Statement on Cerebral Venous Thrombosis (2011):

* treat with full-dose LMWH rather than UFH (Class IIa; Level of Evidence C).
* LMWH in full anticoagulant doses should be continued throughout pregnancy, and LMWH or vitamin K antagonist with a target INR of 2.0-3.0 should be continued for at least 6 weeks postpartum (for a total minimum duration of therapy of 6 months) (Class I; Level of Evidence C).
* future pregnancy is not contraindicated (Class IIa; Level of Evidence B); prophylaxis with LMWH during future pregnancies and the postpartum period is probably recommended (Class IIa; Level of Evidence C).

1. **Antibiotics** for *septic thrombosis* (empirically start with antistaphylococcal a/b).

for cavernous sinus thrombosis - nafcillin or vancomycin + metronidazole + 3rd-generation cephalosporin.

1. **Supportive treatment** similar to arterial stroke (esp. reducing ICP, anticonvulsants\*).

\*routine seizure prophylaxis is not recommended (Class III; Level of Evidence C)

AHA/ASA Scientific Statement on Cerebral Venous Thrombosis (2011):

* In patients with increased ICP, it is reasonable to initiate acetazolamide. Other therapies (lumbar puncture, optic nerve decompression, or shunts) can be effective if there is progressive visual loss. (Class IIa; Level of Evidence C).
* given the frequency of epileptic seizures in children with an acute CVT, ***continuous EEG*** may be considered for individuals who are unconscious or mechanically ventilated (Class IIb; Level of Evidence C).

**Thrombolysis** at present is limited to specialized centers but should be considered for patients with significant deteriorating deficits.

* + all studies concerning use of thrombolytics in CVT involve *intrasinus administration* - either direct instillation into sinus (at time of surgery) or use of microcatheters to reach venous sinus; i.e. no data about systemic IV effects for CVT.
* recent report describes use of ***rheolytic catheter device*** - delivers 6 high-velocity saline jets through halo device at catheter tip → Bernoulli effect breaks up thrombus; particulate debris is directed into effluent lumen for collection into disposable bag.

AHA/ASA Scientific Statement on Cerebral Venous Thrombosis (2011):

steroids are not recommended, even in the presence of parenchymal brain lesions on CT/MRI, unless needed for another underlying disease (Class III; Level of Evidence B)

* steroids (may have a role in CVT by decreasing vasogenic edema, but steroids may enhance hypercoagulability) cause 4.8-fold increased odds of death or dependence (95% CI 1.2 to 19.8).

Surgical

AHA/ASA Scientific Statement on Cerebral Venous Thrombosis (2011):

* **endovascular intervention** may be considered if deterioration occurs despite intensive anticoagulation treatment (Class IIb; Level of Evidence C).
* in patients with neurological deterioration due to severe mass effect or intracranial hemorrhage causing intractable intracranial hypertension, **decompressive hemicraniectomy** may be considered (Class IIb; Level of Evidence C).

**open thrombectomy** and **local thrombolytic therapy** – salvage therapy only for severe neurological deterioration\* (despite adequate anticoagulation).

\*e.g. comatose with papilledema

* surgery is indicated for septic thrombosis if no response to antibiotics in 24 h – remove infected bone (e.g. mastoidectomy), expose and drain sinus; ligate jugular vein (for lateral sinus thrombosis).

Prognosis

Mortality:

untreated cases – 13.8-48%;

treated cases – 12.5% (7% in acute phase, 1% during one year follow-up).

Full recovery:

untreated cases – 29%;

treated cases – 62.5%.

Morbidity:

episodic headaches 11-30%

seizures 8.8-10%

pyramidal signs 11.7%

visual deficits 5.9%

aphasia 9%

memory deficit and depression 17.6%.

* some spontaneously recanalize.
* some form dural AVF.
* 59% (esp. males, polycythemia) developed ***recurrent thrombotic events***.
* prognosis is worse in septic thrombosis.

Follow up

AHA/ASA Scientific Statement on Cerebral Venous Thrombosis (2011):

follow-up CTV or MRV at 3 to 6 months after diagnosis is reasonable to assess for recanalization in stable patients (Class IIa; Level of Evidence C).

Bibliography for ch. “Neurovascular Disorders” → follow this [link >>](http://www.neurosurgeryresident.net/Vas.%20Vascular\Vas.%20Bibliography.pdf)

[Viktor’s Notes℠ for the Neurosurgery Resident](http://www.neurosurgeryresident.net/)

[Please visit website at www.NeurosurgeryResident.net](http://www.neurosurgeryresident.net)